Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile

Abroad (travel likely)RecruitingPHASE2

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Contact: Study coordinator (Winnie YEO, MBBS, MD, FRCP) · winnie@clo.cuhk.edu.hk · 3505 1042
Contact: Study coordinator (Dong LAI, RN) · dong@clo.cuhk.edu.hk · 3505 1138
Contact: Principal Investigator (Winnie MM YEO, MBBS, MD, FRCP)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Tucson, United States

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

HER2 Low Breast Carcinoma · Triple Negative Breast Cancer · Hormone-receptor-positive Breast Cancer

Abroad (travel likely)RecruitingPHASE2

San Francisco, United States

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Hormon Receptor Positive Breast Cancer · Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Dessau, Germany · Alicante, Spain

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

HR+/HER2+ Early Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Nanjing, China · Hangzhou, China